Abstract:Objective To observe the efficacy and safety of rifabutin and furazolidone included triple regimen and minocycline plus furazolidone included quadruple regimen in eradicating refractory H.pylori infection.Methods A total of 146 patients who failed (≥ two times) to treat H.pylori with standard antiH.pylori therapy were selected and divided into esomeprazole,rifabutin and furazolidone treatment group (ERF group,n =74) and esomeprazole,minocycline,furazolidone and bismuth potassium citrate group (EMFB group,n =72).The duration of treatment were both 10 days.Liver and renal functions were examined within three days after therapy.13C or 14 C-urease breath test was performed one month after the medication withdrawal.The patients were followed up once every two weeks during the treatment period.The medication and adverse reactions were recorded in detail.The compliance and rates of adverse events in two groups were compared and analyzed.The eradication rates of the two groups and subgroups were compared by intention-to-treat (ITT) and per-protocol (PP) analyses.The cost-effectiveness of the two groups was evaluated with cost effectiveness analysis (CEA).The cost/effectiveness (C/E) ratio was calculated by PP.Chi-square test and t test were used for statistical analysis.Results There was no significant difference in complicance between ERF group and EMFB group (90.5％ vs.90.3％,P ＞0.05).There was no significant difference in H.pylori eradication rate between ERF group and EMFB group analyzed by ITT (82.4％ vs.84.7％,P ＞0.05).Analyzed by PP,there were no significant differences in H.pylori eradication rate between ERF group and EMFB group (91.0％ vs.93.8％),between male subgroup and female subgroup of ERF group (87.9％ vs.94.1％),between subgroup with age less than 60 years and subgroup with age over 60 years of ERF group (89.7％ vs.92.9％),between male subgroup and female subgroup of EMFB group (89.7％ vs.97.2％) and between subgroup with age less than 60 years and subgroup with age over 60 years of EMFB group (93.6％ vs.94.4％) (all P ＞ 0.05).There were no statistically significant differences in the rate of adverse events between ERF group and EMFB group (20.3％ vs.22.2％),between male subgroup and female subgroup of ERF group (25.0％ vs.15.8％),between subgroup with age less than 60 years and subgroup with age over 60 years of ERF group (26.2％ vs.12.5％),between male subgroup and female subgroup of EMFB group (19.4％ vs.24.4％) and between subgroup with age less than 60 years and subgroup with age over 60 years of EMFB group (24.5％ vs.15.8％)(all P ＞ 0.05).Fixed daily cost,total cost and C/E of ERF group was RMB 59.0 yuan,RMB 590.5 yuan and 648.9,respectively;and the eradication rate was 91.0％ (61/67).Fixed daily cost,total cost and C/E of EMFB group was RMB 32.9 yuan,RMB 329.1 yuan and 350.9,respectively;and the eradication rate was 93.8％ (61/65).Conclusions Rifabutin and furazolidone included triple regimen and minocycline plus furazolidone included quadruple regimen both have good efficacy,safety and compliance in the eradication of refractory H.pylori infection,and the latter is better.

Application of furazolidone in Helicobacter pylori infection eradication

Outcomes of Furazolidone- and Amoxicillin-Based Quadruple Therapy for Helicobacter Pylori Infection and Predictors of Failed Eradication.

Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China

Current Status of Helicobacter Pylori Eradication and Risk Factors for Eradication Failure

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Tetracycline- and Furazolidone-Containing Quadruple Regimen As Rescue Treatment for Helicobacter Pylori Infection: A Single Center Retrospective Study

Furazolidone, Amoxicillin, Bismuth and Rabeprazole Quadruple Rescue Therapy for the Eradication of Helicobacter Pylori

Quadruple Therapy with Vonoprazan 20 Mg Daily As a First-Line Treatment for Helicobacter Pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial.

Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis

[Effect of Furazolidone Quadruple Regimen Plus Dental Plaque Removal Procedures As Rescue Treatment of Refractory Helicobacter Pylori Infection].

The quadruple regimen including Nexium and furazolidone on a choice to treat helicobacter pylori eradication failure

Risk factors of furazolidone-associated fever

Susceptibility-guided Vs. Empirical 10-Day Quadruple Treatment for Helicobacter Pylori-Infected Patients: A Prospective Clinical Trial of First-Line Therapy

[Efficacy and Safety of 14-Day Amoxicillin and Furazolidone-Based Quadruple Rescue Regimen for Eradication of Helicobacter Pylori: a Retrospective Study].

An Update on Eradication of Helicobacter Pylori in Iran: A Review

Comparison the Cost-Efficacy of Furazolidone-Based Versus Clarithromycin-Based Quadruple Therapy in Initial Treatment of Helicobacter Pylori Infection in a Variable Clarithromycin Drug-Resistant Region, a Single-Center, Prospective, Randomized, Open-Label Study

Treatment of peptic ulcer disease with furazolidone

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy

Efficacy and Safety of Rifabutin and Furazolidone Included Triple Regimen and Minocycline Plus Furazolidone Included Quadruple Regimen in Eradicating Refractory Helicobacter Pylori Infection

Regimens and Influencing Factors of Helicobacter pylori Eradication

The Efficacy Of Furazolidone And Metronidazole In The Treatment Of Chronic Gastritis Associated With Helicobacter-(Campylobacter)-Pylori - A Randomized Double-Blind Placebo-Controlled Clinical-Trial